Guideline for evaluating the effects of psychotropic drugs on motor vehicle driving performance in Japan: A tiered approach for the assessment of clinically meaningful driving impairment
Open Access
- 16 April 2024
- journal article
- review article
- Published by Wiley in Neuropsychopharmacology Reports
- Vol. 44 (2) , 308-313
Abstract
In December 2022, the Ministry of Health, Labour and Welfare (MHLW) of Japan issued and implemented the guideline for evaluating the effects of psychotropic drugs on motor vehicle driving performance. This guideline recommends the use of a tiered approach to assess clinically meaningful driving impairment. It is noted that adverse events cannot be solely explained by pharmacokinetics, as the onset and duration of these events vary. Among these adverse events, those affecting alertness, such as drowsiness caused by psychotropic drugs on driving performance, are more frequently observed during initial treatment stages and dose escalation. Hence, when evaluating the effects of psychotropic drugs on driving performance, it becomes crucial to assess the persistence of clinically meaningful impairment. Therefore, the MHLW guideline, developed by the authors, emphasizes the need to assess the temporal profile of adverse events affecting driving in all clinical trials. Additionally, the guideline states that when conducting driving studies, the timing of multiple dosing should consider not only the pharmacokinetics of the investigational drug but also its tolerance.Keywords
Funding Information
- Japan Agency for Medical Research and Development (22mk0101227s0201, 23mk0101227s0202)
This publication has 27 references indexed in Scilit:
- The new guideline for evaluating effects of psychotropic drugs on the performance to drive a motor vehicle in Japan: Comparison with US FDA guidelineNeuropsychopharmacology Reports, 2023
- Driving Performance after Bedtime Administration of Daridorexant, Assessed in a Sensitive SimulatorClinical Pharmacology & Therapeutics, 2022
- On-the-road driving performance the morning after bedtime use of suvorexant 15 and 30 mg in healthy elderlyPsychopharmacology, 2016
- The effects of acute treatment with ramelteon, triazolam, and placebo on driving performance, cognitive function, and equilibrium function in healthy volunteersPsychopharmacology, 2014
- Effects of alcohol on highway driving in the STISIM driving simulatorHuman Psychopharmacology: Clinical and Experimental, 2011
- Zolpidem and zopiclone impair similarly monotonous driving performance after a single nighttime intake in aged subjectsPsychopharmacology, 2010
- Drugs, driving, and models to measure driving impairment2009
- Effects of prolonged‐release melatonin, zolpidem, and their combination on psychomotor functions, memory recall, and driving skills in healthy middle aged and elderly volunteersHuman Psychopharmacology: Clinical and Experimental, 2008
- Next‐day cognition, psychomotor function, and driving‐related skills following nighttime administration of eszopicloneHuman Psychopharmacology: Clinical and Experimental, 2008
- Next-day residual effects of hypnotics in DSM-IV primary insomnia: a driving simulator study with simultaneous electroencephalogram monitoringPsychopharmacology, 2005